Cargando…

Development and Internal Validation of a Multivariable Prediction Model for Adrenocortical-Carcinoma-Specific Mortality

SIMPLE SUMMARY: Adrenocortical carcinoma is a rare and aggressive cancer. Great variability in clinical course is observed, ranging from patients with extreme long survival to aggressive tumors with prompt fatal outcome. This heterogeneity in survival makes it complicated to tailor treatment strateg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ettaieb, Madeleine H. T., van Kuijk, Sander M. J., de Wit-Pastoors, Annelies, Feelders, Richard A., Corssmit, Eleonora P. M., Eekhoff, Elisabeth M. W., van der Valk, Paul, Timmers, Henri J. L. M., Kerstens, Michiel N., Klümpen, Heinz-Josef, van Leeuwaarde, Rachel S., Havekes, Bas, Haak, Harm R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564668/ https://www.ncbi.nlm.nih.gov/pubmed/32971946 http://dx.doi.org/10.3390/cancers12092720

Ejemplares similares

Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing
por: Yin, Anyue, et al.
Publicado: (2020)

Health-Related Quality of Life in Adrenocortical Carcinoma: Development of the Disease-Specific Questionnaire ACC-QOL and Results from the PROFILES Registry
por: Steenaard, Rebecca V., et al.
Publicado: (2022)

Past, Present and Future of Epigenetics in Adrenocortical Carcinoma
por: Ettaieb, Madeleine, et al.
Publicado: (2020)

The Role of the IGF2 Methylation Score in Diagnosing Adrenocortical Tumors with Unclear Malignant Potential—Feasibility of Formalin-Fixed Paraffin-Embedded Tissue
por: Steenaard, Rebecca V., et al.
Publicado: (2023)

Influence of Receptor Polymorphisms on the Response to α-Adrenergic Receptor Blockers in Pheochromocytoma Patients
por: Berends, Annika M. A., et al.
Publicado: (2022)

Efficacy of α-Blockers on Hemodynamic Control during Pheochromocytoma Resection: A Randomized Controlled Trial
por: Buitenwerf, Edward, et al.
Publicado: (2019)

EDP-mitotane in children: reassuring evidence of reversible side-effects and neurotoxicity
por: Steenaard, Rebecca V., et al.
Publicado: (2022)

Health-Related Quality of Life in Adrenocortical Carcinoma
por: Steenaard, Rebecca V., et al.
Publicado: (2019)

How to Differentiate Benign from Malignant Adrenocortical Tumors?
por: Viëtor, Charlotte L., et al.
Publicado: (2021)

Venous thromboembolism in patients with adrenocortical carcinoma after surgery
por: Durmuşoğlu, Jülide, et al.
Publicado: (2020)

Adrenocortical Carcinoma Treatment in the Netherlands: An Analysis From the Netherlands Cancer Registry From 2014 to 2019
por: Steenaard, Rebecca, et al.
Publicado: (2021)

The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures
por: van Koetsveld, Peter M, et al.
Publicado: (2019)

The Importance of an Early and Accurate MEN1 Diagnosis
por: de Laat, Joanne M., et al.
Publicado: (2018)

Patient and Partner Perspectives on Health-Related Quality of Life in Adrenocortical Carcinoma
por: Steenaard, Rebecca V, et al.
Publicado: (2020)

Efficacy and safety of radiation therapy in advanced adrenocortical carcinoma
por: Kimpel, Otilia, et al.
Publicado: (2022)

Non-Conveyance Due to Patient-Initiated Refusal in Emergency Medical Services: A Retrospective Population-Based Registry Analysis Study in Riyadh Province, Saudi Arabia
por: Moafa, Hassan N., et al.
Publicado: (2021)

Variation in on-scene time of emergency medical services and the extent of the difference of on-scene time between genders: a retrospective population-based registry study in Riyadh Province, Saudi Arabia
por: Moafa, Hassan N, et al.
Publicado: (2022)

Disparities between Rural and Urban Areas of the Central Region of Saudi Arabia in the Utilization and Time-Centeredness of Emergency Medical Services
por: Moafa, Hassan N., et al.
Publicado: (2020)

Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients.
por: Haak, H. R., et al.
Publicado: (1994)

Clinical Relevance of Genetic Analysis in Patients With Pituitary Adenomas: A Systematic Review
por: van den Broek, Medard F. M., et al.
Publicado: (2019)

Head-and-neck paragangliomas are associated with sleep-related complaints, especially in the presence of carotid body tumors
por: Havekes, Bas, et al.
Publicado: (2011)

The role of mTOR pathway as target for treatment in adrenocortical cancer
por: De Martino, Maria Cristina, et al.
Publicado: (2019)

Challenges in Von Hippel–Lindau’s disease: PRRT in patients on hemodialysis
por: Ayub, N, et al.
Publicado: (2022)

Diagnosing Nonfunctional Pancreatic NETs in MEN1: The Evidence Base
por: van Treijen, Mark J C, et al.
Publicado: (2018)

Response to Letter to the Editor from Berends et al: “Approach to the Patient: Perioperative Management of the Patient With Pheochromocytoma or Sympathetic Paraganglioma”
por: Berends, Annika M A, et al.
Publicado: (2020)

‘Quality in, quality out’, a stepwise approach to evidence-based medicine for rare diseases promoted by multiple endocrine neoplasia type 1
por: van Beek, Dirk-Jan, et al.
Publicado: (2018)

Non-functioning adrenocortical carcinoma
por: Lenh, Bui-Van, et al.
Publicado: (2021)

IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer
por: De Martino, Maria Cristina, et al.
Publicado: (2019)

Nuclear DNA content and morphological characteristics in the prognosis of adrenocortical carcinoma.
por: Haak, H. R., et al.
Publicado: (1993)

Quality of acute internal medicine: A patient-centered approach. Validation and usage of the Patient Reported Measure-acute care in the Netherlands
por: Kremers, Marjolein N. T., et al.
Publicado: (2020)

Increasing genome instability in adrenocortical carcinoma progression with involvement of chromosomes 3, 9 and X at the adenoma stage
por: Russell, A J, et al.
Publicado: (1999)

What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question
por: Basile, Vittoria, et al.
Publicado: (2021)

Is There a Role for Biomarkers in Surveillance of Pancreatic Neuroendocrine Neoplasms in Von Hippel-Lindau Disease?
por: Naber, Myrthe R, et al.
Publicado: (2021)

Performance of the APOP-screener for predicting in-hospital mortality in older COVID-19 patients: a retrospective study
por: van der Velde, Marleen G. A. M., et al.
Publicado: (2022)

Inhibin Alpha-Subunit (INHA) Expression in Adrenocortical Cancer Is Linked to Genetic and Epigenetic INHA Promoter Variation
por: Hofland, Johannes, et al.
Publicado: (2014)

Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study
por: Terzolo, Massimo, et al.
Publicado: (2023)

Increased Mortality in SDHB but Not in SDHD Pathogenic Variant Carriers
por: Rijken, Johannes A., et al.
Publicado: (2019)

Blood Transcript Profiling for the Detection of Neuroendocrine Tumors: Results of a Large Independent Validation Study
por: van Treijen, Mark J. C., et al.
Publicado: (2018)

FRI192 Serum Steroid Biomarkers For The Differential Diagnosis Of Adrenocortical Carcinoma (ACC) And Adrenocortical Adenoma (ACA)
por: van Rooyen, Desmaré, et al.
Publicado: (2023)

ACTH-independent macronodular adrenocortical hyperplasia reveals prevalent aberrant in vivo and in vitro responses to hormonal stimuli and coupling of arginine-vasopressin type 1a receptor to 11β-hydroxylase
por: Hofland, Johannes, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_o3uiphqfvloiof3fpd72qldqsb